Clinical Trial Update: A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg [Phase 3]

View source ↗

Summary

Phase 3 trial update on OPC-41061 in hepatic edema due to cirrhosis, reporting safety data for 7.5 mg beyond 7 days and dose escalation to 15 mg; results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis

Drugs mentioned

• OPC-41061

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Cirrhosis | Phase 3 | Status: COMPLETED | Results posted: 2014-03-04